Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioArctic AB (BIOAb)

Stockholm
Currency in SEK
Disclaimer
215.4000
-0.4000(-0.19%)
Closed
Fair Value
Unlock Value
Day's Range
211.6000217.8000
52 wk Range
191.5000392.0000
Bid/Ask
215.40 / 215.40
Prev. Close
215.8
Open
215.8
Day's Range
211.6-217.8
52 wk Range
191.5-392
Volume
32,400
Average Volume (3m)
138,028
1-Year Change
-13.49%
Shares Outstanding
88,322,685
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
366.2000
Upside +70.0093%

People Also Watch

63.94
SECARE
-1.63%
86.54
DOMETIC
+1.12%
171.0
AFRY
-1.61%
5.70
STORb
+0.64%
181.30
BIOT
-0.33%
How do you feel today about BIOAb?
Vote to see community's results!
or

BioArctic Company Profile

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. It also develops ABBV-0805, for treating Parkinson’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer’s disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson’s disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.